Drugs / Tucotuzumab celmoleukin
Tucotuzumab celmoleukin
also known as
EMD 273066 · HUKS-IL2 · KSA-INTERLEUKIN-2 · Tucotuzumab celmoleukina · Tucotuzumab celmoleukine
targets EPCAM
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00132522 | May 2005 → Jun 2008 | colorectal cancer, non-small cell lung carcinoma, ovarian cancer, prostate cancer | EMD Serono | Completed | No outcome recorded |
| Phase 1 | NCT00016237 | Dec 2000 → ? | kidney cancer, lung cancer, urinary bladder cancer | EMD Serono | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00408967 | Dec 2006 → May 2008 | ovarian cancer | EMD Serono | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tucotuzumab celmoleukin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00016237 ↗ |
| Known as | EMD 273066 | “Tucotuzumab celmoleukin (EMD 273066)” NCT00408967 ↗ |
| Known as | HUKS-IL2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108660 ↗ |
| Known as | KSA-INTERLEUKIN-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108660 ↗ |
| Known as | Tucotuzumab celmoleukina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108660 ↗ |
| Known as | Tucotuzumab celmoleukine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108660 ↗ |
| Route | Intravenous | “EMD 273066 as a 4-hour IV infusion” NCT00132522 ↗ |
| Target | EPCAM | “Epithelial cell adhesion molecule other” CHEMBL2108660 ↗ |